PCD Connectathon&Showcase 2011-08-16 Webex: Difference between revisions
Jump to navigation
Jump to search
m →Discussion: anticipate Pfizer |
m →Discussion: typos |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 11: | Line 11: | ||
== Participants == | == Participants == | ||
John Donnelly, Al Engelbert, Sarah Hopkins, Sungkee Lee, Khalil Maalouf, John RhoadsKhalid Zubaidi, Manny Furst | |||
Guests: Anie Mathews (FDA), Michael Celeste (Pfizer) | |||
== Discussion == | == Discussion == | ||
| Line 26: | Line 28: | ||
| '''Introductions & Agenda Review''' <br>- Manny | | '''Introductions & Agenda Review''' <br>- Manny | ||
| '''Status/Discussion:''' | | '''Status/Discussion:''' | ||
: No changes were made to the agenda | : No changes were made to the agenda | ||
: | : Discussion Summary was reviewed and approved [[PCD_Connectathon%26Showcase_2011-08-09_Webex]] | ||
'''Decisions/Issues:''' | '''Decisions/Issues:''' | ||
| Line 37: | Line 39: | ||
| '''Status/Discussion:''' | | '''Status/Discussion:''' | ||
Pfizer: | Pfizer/FDA Interest in Reporting Device Events: | ||
:- Michael briefly summarized his last presentation and asked if any EMR vendor was on the call. Sarah offered to look into, and discuss this further. John Donnelly referred to previous adverse event reporting at the Showcase and noted that this is a possible use case if there are interested EMRs. | |||
Other HIMSS12: | |||
:- John Donnelly provided a high level description of the intended flow of the clinical story, integrating various elements. This includes blending PCD more tightly into the story lines and tours. An early description of the use cases will be out within two weeks for use in determining how vendors will register. Use cases will not be incorporated in the registration, but rather use the survey to learn what the setting, profile and actors are that each vendor wishes to bring to the setting. Registration will be around profiles, actors and options. The use case references available shortly will provide an indication of where things are headed, but will be adapted when registration vendor preferences are available. | |||
| Line 43: | Line 49: | ||
'''Action(s):''' | '''Action(s):''' | ||
: | : Michael will send Manny a description to be used in recruiting EMRs from those that participated last year with PCD. | ||
: John Donnelly will send contact information for other EMRs who may be interested in participating with PCD. | |||
|- | |- | ||
| Line 50: | Line 57: | ||
| '''Status/Discussion:''' | | '''Status/Discussion:''' | ||
:- Integration Statements are required for new Supplements. Steve Moore is satisfied that Lynn’s discussions with PCD leadership provided the necessary assurance that the document has sufficient information. | |||
'''Decisions/Issues:''' | '''Decisions/Issues:''' | ||
Latest revision as of 23:22, 16 August 2011
PCD Connectathon & Showcase Fifth Meeting 2011-2012 Cycle, August 16, 2011
Action Items
You can find the Action Items at PCD-Connectathon&Showcase-ActionItemsCycle6-2011-2012
Agenda
You can find the agenda at http://wiki.ihe.net/index.php?title=PCD_Connectathon%26Showcase_WG_2011-12
Participants
John Donnelly, Al Engelbert, Sarah Hopkins, Sungkee Lee, Khalil Maalouf, John RhoadsKhalid Zubaidi, Manny Furst
Guests: Anie Mathews (FDA), Michael Celeste (Pfizer)
Discussion
Item Topic Discussion 1 Introductions & Agenda Review
- MannyStatus/Discussion: - No changes were made to the agenda
- Discussion Summary was reviewed and approved PCD_Connectathon&Showcase_2011-08-09_Webex
Decisions/Issues:
Action(s):
2 HIMSS12
- MannyStatus/Discussion: Pfizer/FDA Interest in Reporting Device Events:
- - Michael briefly summarized his last presentation and asked if any EMR vendor was on the call. Sarah offered to look into, and discuss this further. John Donnelly referred to previous adverse event reporting at the Showcase and noted that this is a possible use case if there are interested EMRs.
Other HIMSS12:
- - John Donnelly provided a high level description of the intended flow of the clinical story, integrating various elements. This includes blending PCD more tightly into the story lines and tours. An early description of the use cases will be out within two weeks for use in determining how vendors will register. Use cases will not be incorporated in the registration, but rather use the survey to learn what the setting, profile and actors are that each vendor wishes to bring to the setting. Registration will be around profiles, actors and options. The use case references available shortly will provide an indication of where things are headed, but will be adapted when registration vendor preferences are available.
Decisions/Issues:Action(s):
- Michael will send Manny a description to be used in recruiting EMRs from those that participated last year with PCD.
- John Donnelly will send contact information for other EMRs who may be interested in participating with PCD.
2 2012 N A Connectathon
- MannyStatus/Discussion: - - Integration Statements are required for new Supplements. Steve Moore is satisfied that Lynn’s discussions with PCD leadership provided the necessary assurance that the document has sufficient information.
Decisions/Issues:
Action(s):
Return to main WG page which has links to individual meeting pages
Return to main PCD Connectathon/Showcase WG page: PCD_Connectathon&Showcase_WG_2011-12